[Complications and effects of the intraperitoneal application in animal experiment].
D000818:Animals; D001284:Atrophy; D001562:Benzimidazoles / Q000494:pharmacology; D001835:Body Weight / Q000187:drug effects; D002482:Cellulose / Q000031:analogs & derivatives / Q000494:pharmacology; D002908:Chronic Disease; D004356:Drug Storage; D004480:Ectromelia; D004912:Erythrocytes / Q000187:drug effects; D005260:Female; D005350:Fibroma / Q000139:chemically induced; D005354:Fibrosarcoma / Q000139:chemically induced / Q000209:etiology; D005549:Foreign-Body Reaction / Q000139:chemically induced; D007274:Injections, Intraperitoneal / Q000009:adverse effects*; D007279:Injections, Subcutaneous; D007509:Irritants / Q000494:pharmacology; D008107:Liver Diseases / Q000209:etiology; D008198:Lymph Nodes; D008297:Male; D051379:Mice; D009150:Mustard Compounds / Q000494:pharmacology; D009374:Neoplasms, Experimental / Q000139:chemically induced*; D010538:Peritonitis / Q000150:complications; D051381:Rats; D012995:Solubility; D014947:Wounds and Injuries / Q000150:complications
D001562:Benzimidazoles; D007509:Irritants; D009150:Mustard Compounds; D002482:Cellulose
Komplikationen und Folgen der intraperitonealen Applikation im Tierexperiment